Conformation and dynamics of the kinase domain drive subcellular location and activation of LRRK2

被引:26
作者
Schmidt, Sven H. [1 ]
Weng, Jui-Hung [2 ]
Aoto, Phillip C. [2 ,3 ]
Boassa, Daniela [4 ,5 ]
Mathea, Sebastian [6 ]
Silletti, Steve [3 ]
Hu, Junru [4 ,5 ]
Wallbott, Maximilian [1 ]
Komives, Elizabeth A. [3 ]
Knapp, Stefan [6 ,7 ]
Herberg, Friedrich W. [1 ]
Taylor, Susan S. [2 ,3 ]
机构
[1] Univ Kassel, Dept Biochem, D-34132 Kassel, Germany
[2] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA
[3] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA
[4] Univ Calif San Diego, Natl Ctr Microscopy & Imaging Res, La Jolla, CA 92093 USA
[5] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA
[6] Goethe Univ Frankfurt, Inst Pharmaceut Chem, D-60438 Frankfurt, Germany
[7] Goethe Univ Frankfurt, Buchmann Inst Mol Life Sci, Struct Genom Consortium, D-60438 Frankfurt, Germany
基金
加拿大创新基金会;
关键词
leucine-rich repeat kinase 2 (LRRK2); hydrogen-deuterium exchange mass spectrometry (HDX-MS); Gaussian accelerated molecular dynamics; kinase regulation; Parkinson's disease; 14-3-3; BINDING; RAF; MUTATIONS; PATHWAY; PHOSPHORYLATION; LOCALIZATION; INHIBITOR; MECHANISM; ENHANCE; LEADS;
D O I
10.1073/pnas.2100844118
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
To explore how pathogenic mutations of the multidomain leucinerich repeat kinase 2 (LRRK2) hijack its finely tuned activation process and drive Parkinson's disease (PD), we used a multitiered approach. Most mutations mimic Rab-mediated activation by "unleashing" kinase activity, and many, like the kinase inhibitor MLi-2, trap LRRK2 onto microtubules. Here we mimic activation by simply deleting the inhibitory N-terminal domains and then characterize conformational changes induced by MLi-2 and PD mutations. After confirming that LRRK2(RCKW) retains full kinase activity, we used hydrogen-deuterium exchange mass spectrometry to capture breathing dynamics in the presence and absence of MLi-2. Solvent-accessible regions throughout the entire protein are reduced by MLi-2 binding. With molecular dynamics simulations, we created a dynamic portrait of LRRK2(RCKW) and demonstrate the consequences of kinase domain mutations. Although all domains contribute to regulating kinase activity, the kinase domain, driven by the DYG(psi) motif, is the allosteric hub that drives LRRK2 regulation.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Inhibition of LRRK2 or Casein Kinase 1 Results in LRRK2 Protein Destabilization
    De Wit, T.
    Baekelandt, V.
    Lobbestael, E.
    MOLECULAR NEUROBIOLOGY, 2019, 56 (08) : 5273 - 5286
  • [2] The dynamic switch mechanism that leads to activation of LRRK2 is embedded in the DFGψ motif in the kinase domain
    Schmidt, Sven H.
    Knape, Matthias J.
    Boassa, Daniela
    Mumdey, Natascha
    Kornev, Alexandr P.
    Ellisman, Mark H.
    Taylor, Susan S.
    Herberg, Friedrich W.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (30) : 14979 - 14988
  • [3] ATP-competitive LRRK2 inhibitors interfere with monoclonal antibody binding to the kinase domain of LRRK2 under native conditions. A method to directly monitor the active conformation of LRRK2?
    Gillardon, Frank
    Kremmer, Elisabeth
    Froehlich, Thomas
    Ueffing, Marius
    Hengerer, Bastian
    Gloeckner, Christian J.
    JOURNAL OF NEUROSCIENCE METHODS, 2013, 214 (01) : 62 - 68
  • [4] Triazolopyridazine LRRK2 kinase inhibitors
    Franzini, Maurizio
    Ye, Xiaocong M.
    Adler, Marc
    Aubele, Danielle L.
    Garofalo, Albert W.
    Gauby, Shawn
    Goldbach, Erich
    Probst, Gary D.
    Quinn, Kevin P.
    Santiago, Pam
    Sham, Hing L.
    Tam, Danny
    Anh Truong
    Ren, Zhao
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (07) : 1967 - 1973
  • [5] Kinase Domain Is a Dynamic Hub for Driving LRRK2 Allostery
    Taylor, Susan S.
    Kaila-Sharma, Pallavi
    Weng, Jui-Hung
    Aoto, Phillip
    Schmidt, Sven H.
    Knapp, Stefan
    Mathea, Sebastian
    Herberg, Friedrich W.
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2020, 13
  • [6] Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation
    Lobbestael, E.
    Civiero, L.
    De Wit, T.
    Taymans, J. -M.
    Greggio, E.
    Baekelandt, V.
    SCIENTIFIC REPORTS, 2016, 6
  • [7] Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease
    Nichols, R. Jeremy
    Dzamko, Nicolas
    Hutti, Jessica E.
    Cantley, Lewis C.
    Deak, Maria
    Moran, Jennifer
    Bamborough, Paul
    Reith, Alastair D.
    Alessi, Dario R.
    BIOCHEMICAL JOURNAL, 2009, 424 : 47 - 60
  • [8] Inhibition of LRRK2 or Casein Kinase 1 Results in LRRK2 Protein Destabilization
    T. De Wit
    V. Baekelandt
    E. Lobbestael
    Molecular Neurobiology, 2019, 56 : 5273 - 5286
  • [9] Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson's disease
    Gonzalez-Hunt, C. P.
    Thacker, E. A.
    Toste, C. M.
    Boularand, S.
    Deprets, S.
    Dubois, L.
    Sanders, L. H.
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [10] Inhibition of LRRK2 kinase activity stimulates macroautophagy
    Manzoni, Claudia
    Mamais, Adamantios
    Dihanich, Sybille
    Abeti, Rosella
    Soutar, Marc P. M.
    Plun-Favreau, Helene
    Giunti, Paola
    Tooze, Sharon A.
    Bandopadhyay, Rina
    Lewis, Patrick A.
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2013, 1833 (12): : 2900 - 2910